Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





CDC Estimates for Latent TB Infection (LTBI) Treatment Costs (in 2020 U.S. dollars)										Related Pages
					**Table 1. Estimated 2020 LTBI Treatment Costs in the United States**
Table 1. Estimated 2020 LTBI Treatment Costs in the United States
LTBI Treatment Regimens
Total Doses
Total Medication Cost
Cost/Dose
Clinic Visits (n)
DOT/Clinic Visits
Supplies Cost
AE Health System Cost
Estimated Total Direct Cost
Patient Time Cost due to DOT
Patient Time Cost due to Clinic Visits
Total Time Cost
AE Societal Cost
Estimated Total Societal Cost6H (300) SAT
130
$25
$0.19
6
$257
$80
$11
$374

$189
$189
$12
$5639H (300) SAT
270
$52
$0.19
9
$338
$92
$17
$499

$273
$273
$18
$7734R (600) SAT
120
$78
$0.65
4
$203
$72
$11
$365

$132
$132
$12
$4983HR (300,600) SAT
90
$76
$0.85
3
$176
$68
$34
$355

$104
$104
$37
$4633HP1 (900,900) 100% SAT
12
$133
$11.12
3
$175
$68
$34
$412

$104
$104
$37
$5203HP1 (900,900) 100% DOT
12
$133
$11.12
3
$412
$68
$34
$648
$27.99
$104
$132
$37
$783
LTBI = latent tuberculosis infection
6H = 6 months of daily doses of 300 milligrams (mg) of isoniazid
9H = 9 months of daily doses of 300 mg of isoniazid
4R = 4 months of daily doses of 600 mg of rifampin
3HR=3 months of daily doses of 300 mg of isoniazid and 600 mg. of rifampin
3HP = 3 months of weekly doses of 900 mg of isoniazid and 900 mg. of rifapentine
DOT = directly observed treatment
SAT = self-administered treatment
AE = adverse events

Excluding medication costs, which have been updated using U.S. Department of Veterans Affairs costs as listed below,1 CDC used values reported in a study from Shepardson et al.,2 which compared 9 months of daily doses of 300 milligrams (mg) of isoniazid using self-administered treatment (9H/SAT) to 3 months of once weekly doses of 900 mg of isoniazid and 900 mg of rifapentine using directly observed treatment (3HP/DOT), to estimate outpatient costs and non-mortality productivity losses in 2020 dollars for patients treated for latent TB infection (LTBI). The methods for updating costs from 2010 to 2020 dollars are described in the following paragraph. Cost estimates exclude those for LTBI testing but include TB disease screening costs.
Table 2 lists costs in 2010 dollars from Shepardson et al.2 that were used, next to their corresponding 2020 cost estimates. Updates to 2020 values for outpatient health services applied the Bureau of Economic Analysis Personal Consumption Expenditures (PCE) index for outpatient health services.3 Productivity losses in the societal perspective were updated using the Bureau of Labor Statistics change in the Average Hourly Earnings of Production and Nonsupervisory Employees index.4
**Table 2. Estimated Cost per Patient in 2010 Compared to 2020**
Table 2. Estimated Cost per Patient in 2010 Compared to 2020
Cost per Patient†
2010 Dollars
2020 DollarsInitial clinic visit
$110.94
$122.48Follow-up clinic visit
$24.37
$26.91Supplies for initial clinic visit
$54.90
$60.61Supplies for follow-up clinic visit
$3.56
$3.93Direct medical costs of 3HP adverse events
$30.89
$34.10Direct medical costs of 9H adverse events
$14.98
$16.54Societal costs of 3HP adverse events
$33.81
$37.33Societal costs of 9H adverse events
$15.95
$17.61Patient productivity lossesInitial clinic visit
$37.05
$48.01Follow-up clinic visit
$21.73
$28.16For DOT
$1.80
$2.33
9H = 9 months of daily doses of 300 mg of isoniazid
4R = 4 months of daily doses of 600 mg of rifampin
3HP = 3 months of weekly doses of 900 mg of isoniazid and 900 mg of rifapentine
DOT = directly observed treatment
†Shepardson et. al.
To calculate the outpatient and productivity cost estimates for 6 months of daily doses of 300 mg of isoniazid monotherapy (6H), 4 months of daily doses of 600 mg of rifampin (4R), 3 months of daily doses of 300 mg of isoniazid and 600 mg of rifampin (3HR), and 3 months of weekly doses of 900 mg of isoniazid and 900 mg of rifapentine using self-administered treatment (3HP/SAT), we extrapolated outpatient and productivity cost estimates for 3HP and 9H from Shepardson et al. by changing the number of clinic visits to match treatment length and by removing directly observed treatment (DOT) costs. We assumed that adverse events for 3HR and 3HP/SAT would be similar to those for 3HP/DOT. Since rifampin alone (4R) typically results in fewer adverse events than for isoniazid containing regimens, we assumed $10 in 2010 dollars or $11 in 2020 dollars in direct medical adverse event costs and $11 in 2010 dollars or $12 in 2020 dollars in societal adverse event costs.
CDC obtained medication costs for treating LTBI from the U.S. Department of Veterans Affairs (VA)1 by National Drug Code (NDC) product identifier. While TB programs obtain their TB medications through the Health Resources and Services Administration (HRSA) 340B program of prices negotiated directly with pharmaceutical companies, neither HRSA nor TB programs are permitted to share their price data with CDC. So, CDC estimated TB medication costs from those obtained from the VA system, which similarly negotiates with pharmaceutical companies for prices much lower than advertised retail and wholesale prices. Costs were calculated for typical doses in milligrams (mg) for isoniazid (INH) plus $.02/dose for vitamin B6, rifampin (RIF), and rifapentine (RPT).
**Table 3. Medication Cost Estimates***
Table 3. Medication Cost Estimates*
Quantity
Dose/Day
Dose/Day
VA
VAMedication
NDC
Mg
Tablets per bottle
# Tablets
Dose in mg
$/Bottle
$/DoseINH(300)+B6
00555-007
300
100
1
300
$17.42
$0.19RIF (600)
00904-528
300
200
2
600
$65.13
$0.65RPT (900)
00088-210
150
24
6
900
$42.16
$10.54
INH = isoniazid
RIF = rifampin
RPT = rifapentine
*U.S. Department of Veterans Affairs. National Acquisition Center. https://www.vendorportal.ecms.va.gov/nac/Pharma/Listexternal icon Accessed February 2019.

**Inflation Adjustment Indices**
Inflation Adjustment Indices
2010 to 2020$
Outpatient Personal Consumption Expenditures
1.104062010 to 2020$
Average Hourly Earnings
1.29569References1 US Department of Veterans Affairs. National Acquisition Center. https://www.vendorportal.ecms.va.gov/nac/Pharma/Listexternal icon Accessed February 2020.
2 Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. *Int J Tuberc Lung Dis.* 2013;17(12):1531-7. doi: 10.5588/ijtld.13.0423. PubMed PMID: 24200264; PubMed Central PMCID: PMC5451112.
3 Bureau of Economic Analysis Personal Consumption Expenditures (PCE) indices for hospital and outpatient healthcare services. Table 2.4.4 https://apps.bea.gov/iTable/iTable.cfm?reqid=19&step=2#reqid=19&step=2&isuri=1&1921=surveyexternal icon
4 Average hourly earnings of production and nonsupervisory employees, total private, not seasonally adjusted. https://data.bls.gov/cgi-bin/srgateexternal icon series CEU0500000008.
							
					
						Page last reviewed:  October 12, 2021					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue